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Abstract
Purpose: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part
because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown
to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease
this protection and thus sensitize resistant tumor cells to the effects of radiation therapy.
Materials and methods: Eight human GBM cell lines were screened for radiosensitivity to the
small-molecule c-Met inhibitor MP470 with colony-count assays. Double-strand (ds) DNA breaks
was quantified by using antibodies to gamma H2AX. Western blotting demonstrate expression of
RAD51, glycogen synthase kinase (GSK)-3β, and other proteins. A murine xenograft tumor flank
model was used for in vivo radiosensitization studies.
Results: MP470 reduced c-Met phosphorylation and enhanced radiation-induced cell kill by 0.4
logs in SF767 cells. Cells pretreated with MP470 had more ds DNA damage than cells treated with
radiation alone. Mechanistically, MP470 was shown to inhibit dsDNA break repair and increase
apoptosis. MP470 influences various survival and DNA repair related proteins such as pAKT,
RAD51 and GSK3β. In vivo, the addition of MP470 to radiation resulted in a tumor-growth-delay
enhancement ratio of 2.9 over radiation alone and extended survival time.
Conclusions: GBM is a disease site where radiation is often used to address both macroscopic
and microscopic disease. Despite attempts at dose escalation outcomes remain poor. MP470, a
potent small-molecule tyrosine kinase inhibitor of c-Met, radiosensitized several GBM cell lines
both in vitro and in vivo, and may help to improve outcomes for patients with GBM.
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Introduction
The management of malignant gliomas continues to pose
a difficult therapeutic challenge. Use of radiation therapy
and chemotherapy after maximal tumor debulking can
improve both local control and survival for some patients
with malignant gliomas [1]. Unfortunately, despite adju-
vant therapy nearly all patients with glioblastoma multi-
forme (GBM) will eventually develop tumor recurrence
and die of the disease. Patterns-of-failure studies con-
ducted after primary therapy for GBM have shown that
75%-90% of patients experience tumor recurrence within
2 cm of the resection margin [2]. Attempts to increase the
local radiation dose have not led to any meaningful
improvement in survival when tested in randomized trials
[3]. The most likely cause of recurrence is believed to be
intrinsic radioresistance, mediated in part by efficient
DNA repair. This suggests that interventions aimed at
modifying cellular resistance to radiation or chemother-
apy may confer a survival benefit.
Hepatocyte growth factor (HGF) is a multifunctional het-
erodimeric protein typically produced by mesenchymal
cells. Its pleiotropic activities are mediated through its cel-
lular receptor, a transmembrane tyrosine kinase encoded
by the proto-oncogene c-Met. In malignant cells, HGF has
been shown to protect cells from death induced by a vari-
ety of DNA-damaging agents, including radiation and
topoisomerase inhibitors [4]. Interestingly HGF/SF not
only blocked DNA damage-induced apoptosis but also
enhanced the rate of repair of DNA strand breaks [5]. HGF
also functions as an autocrine or paracrine growth factor
and activates a program of cell dissociation and motility
coupled with increased protease production that has been
shown to promote cellular invasion [6,7]. HGF and c-Met
are co-expressed and often overexpressed in a broad spec-
trum of human solid tumors including lung, breast, and
brain malignancies [7,8]. Therefore, the overexpression of
c-Met by GBM cells suggests that blocking HGF or its
receptor c-Met might be an attractive strategy when com-
bined with conventional treatment for the treatment of
GBM. A recent review of this approach indicates that sev-
eral novel inhibitors of the tyrosine kinase activity of c-
Met have been developed and tested as a single agent or in
combination with cytoxic chemotherapy [9]. Although it
has previously been shown that targeting HGF or c-Met
expression using ribozyme radiosensitizers in GBM cells
in vitro and xenograft tumor in vivo [10], demonstration
of clinically useful inhibitors of the tyrosine kinase activ-
ity of c-Met combined with radiation have not been previ-
ously tested in GBM models.
In the work presented here, a novel inhibitor of c-Met
tyrosine kinase, MP470 [11], was tested for its ability to
radiosensitize GBM cells both in vitro and in vivo.
Materials and methods
Cell culture
All of the human GBM cell lines tested (SF763, SF268,
SF295, SF126, SF188, SF767, U-87, and SF210) were
obtained from the University of California, San Francisco,
and maintained in Dulbecco's Modified Eagle Medium
supplemented with 10% fetal calf serum and 1% penicil-
lin-streptomycin [12]. Cells were incubated at 37°C in a
5% CO2 incubator. MP470 (SuperGen, Dublin, CA) was
stored in the dark at 4°C until use, when it was dissolved
in dimethyl sulfoxide and used at a final concentration of
5.0-10 μM. The drug was added to cells 1 hour before irra-
diation unless otherwise specified. Control cells were
treated with equal volumes of dimethylsulfoxide. A
cobalt-60 teletherapy unit (Atomic Energy of Canada Lim-
ited Theratron-80) was used to irradiate the GBM cells at
a dose rate of 2 Gy/min.
Cell proliferation assay
The cytotoxicity of MP470 was assessed in vitro in all eight
cell lines by using an MTS assay performed in a 96-well
plate format. Cells were plated with a multichannel pipet-
ter and MP470 (to a final concentration of 5 μM) was
added to triplicate wells 24-48 hours later, after which the
plates were incubated for up to 4 days. The MTS assay was
done with a CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay kit as per the manufactures recom-
mendations (Cat #G5421, Promega, Madison, WI). The
IC50  (the concentration that inhibited proliferation in
50% of the samples) was determined from standard
curves.
In vitro clonogenic assay
The eight human GBM cell lines were cultured as
described above, harvested, counted, and seeded onto 60-
mm petri dishes at specific cell densities. MP470 (5 μM)
was added 1 hour before the cells were irradiated with sin-
gle doses ranging from 2 to 8 Gy, after which the cells were
returned to a 37°C incubator and cultured for 14 days in
the presence of the MP470 before fixation. Cells were
fixed for 5 minutes with 3:1 methanol: acetic acid solution
and stained for 5 minutes with 0.5% crystal violet (Sigma,
St. Louis, MO) in methanol. Colonies were counted with
a Colcount automated colony counter (Optronix, Milton
Port, Oxford, UK) using the discrete colony mode. The
surviving fraction was calculated as (mean colony
counts)/(cells plated) × (plating efficiency), where plating
efficiency was defined as (mean colony counts)/(cells
plated for unirradiated controls). All experiments were
done in duplicate in 3 independent experiments and aver-
aged data points represent the means ± standard devia-
tions (SD).Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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Apoptosis assay
Near-confluent SF767 cells were pretreated with 5 μM
MP470 irradiated (8 Gy), and analyzed 4 hours later as
follows. Briefly, after pretreatment with MP470 for 5
hours, cells were suspended in phosphate-buffered saline
(PBS, made by dissolving 8 g NaCl, 0.2 g KCl, 1.44 g
Na2HPO4, and 0.24 g KH2PO4 in 800 mL of H2O) (pH
7.2) containing acridine orange (1 μg·mL-1) and RNAse A
and then co-stained with 1 μg·mL-1 ethidium bromide
(all reagents from Sigma); cells were then washed and
examined under a fluorescence microscope (×150, Olym-
pus, Center Valley, PA; exciting filter BG12, barrier filter 0-
5.30). For quantitative analyses, 200 cells were counted
and the percentages of necrotic and apoptotic cells calcu-
lated.
γ-H2AX assay
Double-stranded (ds) DNA breaks lead to the formation
of γ-H2AX, a unique histone complex. We used a γ-H2AX
antibody (Upstate Cat #05-636, Millipore, Billerica, MA)
to visualize dsDNA breaks as follows. Cells were plated in
chamber slides, grown for 48 hours, and treated with 5
μM MP470, one hour later, the cells were irradiated with
4 Gy and processed either 1 hour or 8 hours later. Cells
were first fixed in 4% paraformaldehyde and incubated
with the primary antibody against γ-H2AX. The primary
antibody was then washed off, and a secondary antibody
conjugated to fluorescein isothiocyanate (FITC) was
added to the slides. DNA damage was visualized by using
confocal microscopy. Median intensity of each cell was
calculated using Photoshop and a 2 sided t-test was used
to calculate the difference.
Comet assay
dsDNA breaks were visualized by using a neutral comet
assay (Cat #4250-050-K, Trevigen, Gaithersburg, MD).
Cells were plated on 10-cm BD Falcon Cell Culture Plates
(BD, Franklin Lakes, NJ), incubated for 2 days, treated
with 10 μM MP470 or dimethylsulfoxide (control) for 1
hour, and then irradiated with 8 Gy. Cells were then
trypsinized, placed on glass slides, and subjected to elec-
trophoresis according to the manufacturer's instructions.
dsDNA breaks were measured by olive tail movement,
(OTM), defined as (tail length) × (the fraction of total
DNA in the tail)[13]. OTM values were calculated with
TriTek Comet Score V 1.5 software (The TriTek Corpora-
tion, Sumerduck, VA). Data points represent means ± SDs
from triplicate experiments.
Western blotting
Cells were plated on 10-cm petri dishes and grown for 24-
48 hours. MP470 was then added at a concentration of 10
μM (in 100% dimethlysulfoxide) for maximum inhibi-
tion. Cells were incubated with the MP470 for 24 hours
(unless otherwise specified) before being irradiated with 4
Gy. After irradiation, cells were lysed on the plates by add-
ing 350 μL of sodium dodecyl sulfate lysis buffer (20 mM
HEPES [pH 7.9], 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% NP40, 1 mM DTT, 1 mM phenylmethylsulfo-
nyl fluoride, 1 mg/mL aprotinin, 1 mg/mL leupeptin, 250
mg/mL benzamide, 50 mM NaF, and 1 mM NaO3V4). The
lysate was transferred to a 1.5-mL microcentrifuge tube,
boiled for 5 minutes with intermittent vortexing, and then
centrifuged for 5 minutes at 10,000 rpm, after which the
supernatant was transferred to a new microcentrifuge
tube. Lysates were subjected to electrophoresis on 10%-
20% HCl pre-poured gels (Cat #161-1108, Bio-Rad, Her-
cules, CA). The proteins were then transferred to nitrocel-
lulose paper and probed with the appropriate antibodies
under the conditions recommended by the suppliers. The
following antibodies were used Phospho-AKT (Ser 473
Cat, #4058), glycogen synthase kinase (GSK)-3β with
Phospho-GSK-3β (Ser9, #9336) Cell Signaling Technol-
ogy, Danvers, MA), RAD51 H-92 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and c-Met phosphospecific Anti-c-
Met [pY1003] (Cell Signaling Technology) [14].
siRNA experiments
siRNA to c-Met (sc-29397) and control siRNA (sc-37007)
were purchased from Santa Cruz Biotechnology. The
transfection reagent Lipofectamine was from Invitrogen
(Carlsbad, CA). U87 cells were grown to 70% confluence
and transfected with siRNA at a final concentration of 100
nM. Seventy-two hours later, the cells were lysed for west-
ern blotting analysis as described above.
Animal experiments
To create subcutaneous tumors, cells (4 × 106 per animal)
were implanted in the flanks of 32 outbred athymic nude
mice, 8 per arm (Taconic, Germantown, NY). U87 cells
were chosen for their high level of c-Met expression and
ability to rapidly produce tumors. Twenty-five days after
the cells were injected, animals were pair-matched (based
on tumor volume) and assigned to one of four treatment
groups: control; MP470 (60 mg/kg) alone; radiation
alone (2 Gy per day × 10 days); and MP470 + radiation.
MP470 was delivered daily by gavage at a dose of 60 mg/
kg in peanut oil starting on day 25 for 14 consecutive
days. Radiation was started on day 27 and consisted of 2
Gy per day delivered to the tumor by a cobalt-60 irradiator
(Theratron-80).
Radiation was delivered daily, 5 days per week for 2
weeks, at 1 hour after the MP470 treatment. The total
cumulative dose delivered to the tumor was thus 20 Gy.
Animals were euthanized by CO2 asphyxiation when the
tumor volume reached 2000 mm3, as required by our
institutional animal care and use committee protocol
#07-029. All remaining animals were euthanized on day
48. Tumors were measured with calipers every 5 days andRadiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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the volume calculated according to the formula (a2 - b/2),
where a is the smallest diameter and b is the largest diam-
eter of the tumor.
Tumor growth delay was expressed in absolute and nor-
malized terms as follows. Absolute growth delay (AGD)
was defined as the number of days for tumors in the radi-
ation-only and the MP470 + radiation groups to reach
1,500 mm3 minus the number of days for tumors in the
control group to reach the same size. Normalized growth
delay (NGD) was calculated as the number of days for
tumors in the combined-therapy group to reach 1,500
mm3 minus the number of days for tumors in the MP470-
only group to reach 1,500 mm3. The enhancement factor
was then determined by dividing the NGD for the group
receiving MP470 plus radiation by the AGD for the group
given radiation alone. All statistical analyses were carried
out with Stata 9.2 for Windows (College Station, TX), and
P values < 0.05 were considered significant.
Results
Cytotoxicity and radiosensitization
The small-molecule tyrosine kinase inhibitor MP470 was
designed to target c-Met, although it also inhibits the c-Kit
receptor and platelet-derived growth factor receptor at
nanomolar levels [11]. To evaluate its effect on prolifera-
tion eight GBM cell lines were used in an MTS assay. All
eight cell lines proved to be sensitive to MP470 alone,
with IC50 values ranging from 1 μM to 10 μM (median 5
μM). To test its potential as a radiosensitizer, we assessed
clonogenic survival after 4 Gy of the same eight GBM cell
lines after a 1-hour treatment with MP470 followed by a
single radiation dose (Fig. 1). Various levels of response
were seen in the different cell lines, with 3 of the 8 GBM
Effect of MP470 and radiation on clonogenic survival of eight GBM cell lines Figure 1
Effect of MP470 and radiation on clonogenic survival of eight GBM cell lines. The combination of MP470 (5 μM) plus 
radiation (4 Gy) produced the most cell killing of any treatment condition, but the extent of the responses varied among the 
different cell lines. The radiosensitizing effect of MP470 was most effective in the SF767, U87, and SF210 cell lines. Each bar is 
the mean of 3 experiments and error bars indicate standard deviation.Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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lines appearing to have a greater then additive response
when MP470 was combined with XRT. SF767 cells were
chosen to assesses for clonogenic survival in response to
increasing doses of radiation (0 to 8 Gy) and MP470 had
a radiosensitizing effect at all radiation doses tested,
MP470 increased cell kill by 0.5 log compared to 4 Gy
alone (Fig. 2).
MP470 inhibits GSK3β and induces apoptosis
Having established the ability of MP470 to sensitize GBM
cells to radiation, we next wanted to validate that it was
acting through c-Met. SF767 cells demonstrate the pres-
ence of pMet and treatment with MP470 reduced c-Met
phosphorylation (Fig. 3A), as assessed by immunoblot-
ting analysis. In order to confirm MP470's mechanism of
action we evaluated a known downstream pathway of c-
Met, phosphatidylinositol 3-kinase/Akt, in SF767 cells
[15]. A 1-hour incubation with MP470 led to a reduction
in pAkt protein in SF767 cells (Fig. 3B). To determine the
effect of this reduction in pAkt on cell survival, we evalu-
ated apoptosis and necrosis induced by radiation (8 Gy),
alone or after a 1-hour pretreatment with MP470, using
an acridine orange assay. MP470 alone had no effect on
cell death, and radiation alone induced a mild increase in
cell death (this stands in contrast to the percent of death
seen in a clonogenic assay, since the majority of radiation
induced cell death is from mitotic division and not apop-
totic). The combination of MP470 followed by radiation
(8 Gy), however, killed 75% of the cells (Fig. 4A). We next
postulated that GSK3β, a key regulator of the extrinsic
apoptotic pathway [16], could play a role in this induc-
tion of apoptosis, as it is strongly regulated by Akt. We
found that pretreatment with MP470 resulted in increased
phosphorylation of GSK3β at serine-9 (Fig. 4B), a site
known to inhibit GSK3β [16].
Influence of MP470 on repair of dsDNA breaks
To test the hypothesis that MP470 enhances radiation-
induced cell death by influencing the repair of dsDNA
breaks, we measured levels of γ-H2AX. At 1 hour after irra-
diation, both the control cells and the MP470-treated cells
showed comparable numbers of γ-H2AX foci, suggesting
that MP470 does not enhance the initial level of radiation
induced dsDNA breaks. In order to detect an influence of
MP470 on repair, we quantified the level of γ-H2AX foci
several hours after irradiation. At 8 hours after irradiation,
cells treated with XRT had a median densitometry inten-
sity of 71 compared to 127 for cells treated with MP470
and XRT p = 0.04. (Fig. 5). To further evaluate MP470's
affect on dsDNA repair, we supplemented our γ-H2AX
results with a comet assay. At 1 hour after irradiation,
SF767 cells treated with either radiation alone (8 Gy) or
with 10 μM MP470 followed by irradiation showed simi-
lar levels of DNA damage, higher doses of MP470 and
radiation were used here due to the low sensitivity of the
comet assay. However, at 8 hours after irradiation, dsDNA
repair was greatly inhibited in the cells that had been pre-
treated with MP470 22 ± 3.1 tail DNA (%), for 8-Gy irra-
diation alone and 35 ± 4.3 tail DNA (%), for MP470
followed by 8-Gy irradiation). This increase in OTM sug-
gests that MP470's radiosensitizing effect may be partially
mediated through inhibition of dsDNA repair. RAD51 is
a key regulator of homologous recombinational repair
[17,18] and our prior work has demonstrated that RAD51
level at the time of surgical resection is an independent
prognosticator of survival in GBM patients [19], thus we
evaluated whether MP470 could affect RAD51. RAD51
expression was noted to be increased (24 hrs) after the
cells were irradiated. Pretreatment with MP470 decreased
RAD51 expression in nonirradiated cells and suppressed
the increase in expression prompted by radiation (Fig.
6A). This effect was dose-dependent, with the strongest
suppression at MP470 concentrations exceeding 5 μM. To
verify that MP470 was indeed decreasing RAD51 expres-
sion and not simply shifting cells into a quiescent cell
cycle state (G0) characterized by lower levels of RAD51,
we tested the effect of MP470 on cell cycle distribution
and found it had no influence. To establish that RAD51
suppression was directly associated with c-Met inhibition,
we silenced c-Met expression using siRNA, which also
demonstrated inhibition of RAD51 (Fig. 6B).
In vivo radiosensitization studies
To validate the in vitro results, we implanted GBM cells
subcutaneously in the flanks of nude mice and treated
Clonogenic survival of SF767 cells treated with MP470 fol- lowed by irradiation in a range of radiation doses Figure 2
Clonogenic survival of SF767 cells treated with 
MP470 followed by irradiation in a range of radiation 
doses. Radiation at all doses had a moderate suppressive 
effect on clonogenic survival, and that effect was enhanced by 
pretreatment with MP470. Each data point represents the 
mean of 3 experiments ± SD.Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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those mice with MP470, irradiation, or both, with 8 ani-
mals per group. Treatment started on day 25 with MP470
which was given daily for 14 consecutive days, XRT was
started on day 27 using a total of 20 Gy in 10 daily frac-
tions, to the tumor alone. On day 48 after implantation
the experiment was terminated and the tumors were
measured. As shown in Fig. 7A, MP470 increased the AGD
from 6.1 ± 2.3 days with radiation alone to 17.7 ± 2.8 days
with the combination, resulting in an enhancement ratio
of 2.9 (Table 1). Survival rates were evaluated on the final
day of the experiment. At that time, survival rates were 0%
in the vehicle-control or MP470-only groups, 50% in the
radiation-only group (P  = 0.035), and 87.5% in the
MP470-plus-radiation group (P = 0.001) (Fig. 7B).
Discussion
The small molecule MP470 is a potent c-Met antagonist
that is cytotoxic to a variety of cell lines in vitro [11]. In this
report, we demonstrated that concurrent inhibition of c-
Met in combination with irradiation led to both reduced
Western blot analysis of SF767 cell lines in response to MP470 Figure 3
Western blot analysis of SF767 cell lines in response to MP470. (A) Treating SF767 cells with MP470 (10 μM) for 1 hr 
followed by stimulation with pervanadate led to reduced phosphorylation of c-Met [pY1003] in a dose-dependent manner, com-
pared to DMSO control. (B) SF767 cells treated with MP470 (10 μM) for 1 hr showed reduced expression of pAkt protein.
(A) Apoptosis and necrosis, quantified using an acridine orange assay, in SF767 cells after treatment with radiation, MP470, or  both. MP470 (5 μM) alone had no effect on the proportion of dead cells Figure 4
(A) Apoptosis and necrosis, quantified using an acridine orange assay, in SF767 cells after treatment with radi-
ation, MP470, or both. MP470 (5 μM) alone had no effect on the proportion of dead cells. Radiation (8 Gy) by itself 
induced some necrotic cell death but little apoptosis. However, the combination of MP470 followed by radiation greatly 
increased the proportions of both necrotic and apoptotic cells. Performed in triplicate: bars indicate mean ± SD. (B) Western 
blot analysis of SF767 cells treated with radiation (4 Gy) alone had no influence on the expression of glycogen synthase kinase 
(GSK)3β phosphorylated at serine 9; however, treatment with MP470 (10 μM) or MP470 for 24 hrs followed by radiation 
enhanced the expression of this phosphorylated protein.Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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dsDNA repair and enhanced apoptosis in GBM. Our in
vitro findings were supported by our in vivo observations
using a xenograft model in nude mice. In this model,
MP470 by itself, at a dose of 60 mg/kg, had no effect on
tumor size or survival; radiation by itself was somewhat
more effective in reducing tumor volume and improving
survival; but the combination of radiation plus MP470
produced the best response in terms of both local control
and survival.
High-grade glial neoplasms of the brain continue to be
one of the most challenging malignancies to treat, and
their poor prognosis has improved only marginally over
the past four decades (survival rates of 10%-20% at 2
years) [20]. Postoperative radiation provides a clear sur-
vival advantage for patients with gliomas, yet the majority
of disease recurrences present within 2 cm of the postop-
erative bed-the very place targeted by the radiation. Unfor-
tunately, attempts to escalate treatment doses to the
tumor bed have provided only modest benefit [21]. To
better understand why requires evaluating the cellular and
molecular interactions in the resistant tumor cells. The
pathway to malignancy consists of multiple genetic muta-
tions, often in key regulators of the cell cycle or DNA
repair process. These alterations allow cancer cells to not
only divide unchecked, but also to repair DNA damage at
Photomicrographs of γ-H2AX foci detected in irradiated SF767 cells Figure 5
Photomicrographs of γ-H2AX foci detected in irradiated SF767 cells. Cells were irradiated with 4 Gy, fixed 8 hours 
later, and then stained with anti-γ-H2AX antibodies. Original magnification × 1,000 (values indicate mean intensity, based on 
densitometry). (A) γ-H2AX foci in SF767 cells treated with radiation alone. (B) Pretreatment with 5 μM MP470, before radia-
tion lead to increased γ-H2AX foci. (C) Radiation plus MP470 resulted in a median γ-H2AX foci intensity of 127 compared to 
71 for radiation alone p = 0.04.Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
Page 8 of 10
(page number not for citation purposes)
an accelerated or more efficient rate. One of the genes
implicated in homologous recombination repair of
dsDNA damage is RAD51. Prior work from our lab has
demonstrated that RAD51 expression levels at the time of
initial surgical resection are an independent prognostica-
tor of survival for GBM patients receiving radiation [19].
In the present paper, we evaluated whether MP470 could
influence RAD51 expression in GBM tumors cell and
found that pretreatment with MP470 inhibited XRT
induced expression of RAD51. This compliments our
prior GBM tissue microarray findings that 70% of recur-
rent GBM tumors, treated with XRT, were found to have
elevated RAD51 at the time of recurrence [19]. Paradoxi-
cally, this suggests that the ability of malignant cells to
repair dsDNA damage can be enhanced by the very agents
used to treat malignancies. The stimulation of RAD51 by
radiation may explain why current therapies temporarily
improve local control but fail to offer definitive cures.
Clearly, substantial improvements in local control and
survival of patients with GBM will require targeting
(inhibiting) the molecular machinery that mediates the
development of resistance.
To our knowledge, this is the first demonstration that
MP470, an orally available c-Met antagonist, causes radi-
osensitization of several GBM cell lines. We have shown
evidence that supports a mechanism of action consistent
with a decrease in dsDNA break repair, along with
enhanced radiation-induced apoptosis. Other investiga-
tors have shown that c-Met inhibition can enhance radia-
tion-induced tumor cell death in vitro using a retrovirally
based approach that would not be a clinically viable
option, although it did serve as an important proof of
concept [10]. This stands in contrast to MP470, which is
well tolerated in animals, with no observable adverse
effects from daily administration of 2,000 mg/kg to rats
(A) Western blot analysis of SF767 cells showed constitutive  expression of the RAD51 which is elevated further after irra- diation Figure 6
(A) Western blot analysis of SF767 cells showed con-
stitutive expression of the RAD51 which is elevated 
further after irradiation. MP470 (10 μM) inhibited both 
constitutive and radiation-induced expression of RAD51 pro-
tein. (B) Cells treated with siRNA to c-Met for 48 hours led 
to suppression of c-Met and reduced expression of RAD51.
Tumor volume and survival in mice with subcutaneous U87 MG xenografts treated with MP470 and radiation Figure 7
Tumor volume and survival in mice with subcutaneous U87 MG xenografts treated with MP470 and radiation. 
Tumor volume of 1,500 mm3 was used as a baseline for calculating tumor growth delays, and mice were euthanized once they 
reached 2000 mm3. (A) Irradiation alone resulted in a modest AGD of 6.1 ± 2.3 days, while the combination of MP470 plus 
irradiation produced an AGD of 17.7 ± 2.8 days, resulting in an enhancement ratio of 2.9 (Table 1). (B) Kaplan-Meier survival 
rates on day 48 (the final day of the experiment) were 0% in both the control and MP470-alone groups, 50% in the radiation-
only group (P = 0.035), and 87.5% in the MP470 + radiation group (P = 0.001). Each data point represents the mean of 8 
tumors; bars indicate standard error.Radiation Oncology 2009, 4:69 http://www.ro-journal.com/content/4/1/69
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and 240 mg/kg to dogs [22]. This initial work on MP470
provided the foundation to support a phase I trial, to
establish the maximum tolerated dose of MP470 in
humans. Our work reported here suggests that c-Met inhi-
bition can offer therapeutically relevant radiosensitization
and potentially improve the therapeutic ratio in radiation-
resistant tumors such as GBM.
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